摘要
目的探究四种肿瘤标志物:癌胚抗原(CEA)、细胞角蛋白19血清片段21-1(CYFRA21-1)、糖类抗原(CA125)、鳞状细胞癌相关抗原(SCC)在非小细胞肺癌诊断及病理分析中的应用价值。方法选择2017年4月—2018年4月本院收治的700例肺部疾病患者为研究对象,根据患者病情分为对照组(良性肺部疾病,372例)和研究组(非小细胞肺癌,328例)两组。研究组根据患者不同病理类型又分为肺鳞癌组(201例)和肺腺癌组(127例)两组。观察比较两组患者体内四种肿瘤标志物的水平以及不同种类非小细胞肺癌内四种肿瘤标志物的阳性率。结果研究组患者体内的CEA、CA125、SCC肿瘤标志物的水平明显低于对照组,CYFRA21-1肿瘤标志物的水平明显高于对照组,差异有统计学意义(P<0.05);研究组中肺鳞癌患者中的SCC阳性率水平明显高于肺腺癌患者,差异有统计学意义(P<0.05)。结论根据癌胚抗原(CEA)、细胞角蛋白19血清片段21-1(CYFRA21-1)、糖类抗原(CA125)、鳞状细胞癌相关抗原(SCC)在不同患者血清内的水平差异使其作为4种血清肿瘤标志物检测非小细胞肺癌具有较高的特异性,能够提高对患者非小细胞肺癌诊断的敏感度,对非小细胞肺癌患者的诊断以及病理分析有较高的临床价值。因此,广大医学工作者应该加大对肿瘤标志物类型及其在不同疾病内含量水平差异的研究,不断创新非小细胞肺癌的检测方法,为临床上治疗非小细胞肺癌提供一种有效的检测依据。
Objective To explore the application value of four tumor markers:carcinoembryonic antigen(CEA),cytokeratin 19 serum fragment 21-1(CYFRA21-1),carbohydrate antigen(CA125),squamous cell carcinoma associated antigen(SCC)in the diagnosis and pathological analysis of non-small cell lung cancer.Methods A total of 700 patients with pulmonary disease who were admitted to our hospital from April 2017 to April 2018 were selected as the study subjects,and they were divided into the control group(benign lung disease,n=372)and the study group(non-small cell lung cancer,n=328).Among lung cancer patients,201 were lung squamous cell carcinoma and 127 were lung adenocarcinoma.The levels of four tumor markers and the positive rate of four tumor markers in different types of non-small cell lung cancer were observed and compared in the two groups of patients.Results The levels of tumor markers CEA,CA125,SCC in the study group were significantly lower than those in the control group,while the level of CYFRA21-1 was significantly higher than the control group(P<0.05).In the study group,the positive rate of SCC in lung squamous cell carcinoma group was significantly higher than that in the lung adenocarcinoma group,the difference was statistically significant(P<0.05).Conclusions The distinct serum levels of Carcinoembryonic Antigen(CEA),Cytokeratin-19 Fragment(CYFRA 21-1),Carbohydrate Antigen(CA 125),and Squamous Cell Carcinoma Antigen(SCC)among patients confer high specificity for the detection of non-small cell lung cancer(NSCLC).These markers enhance the sensitivity of diagnosing NSCLC and hold significant clinical value for both diagnosis and pathological analysis in NSCLC patients.Consequently,medical professionals should intensify research into the types of tumor markers and the variations in their levels across different diseases.Innovation in detection methods for NSCLC is essential to provide an effective basis for clinical diagnosis and treatment of the disease.
作者
胡佳捷
余帆
曹燕珍
杨丽丽
Hu Jiajie;Yu Fan;Cao Yanzhen;Yang Lili(Department of Pathology,the Affiliated Cancer Hospital of Xinjiang Medical University,Urumqi,Xinjiang 830011,China)
出处
《齐齐哈尔医学院学报》
2024年第16期1560-1563,共4页
Journal of Qiqihar Medical University
基金
新疆维吾尔自治区自然科学基金
面上项目(2022D01C302)。
关键词
肿瘤标志物
非小细胞肺癌
诊断
病理分析
Tumor markers
Non-small cell lung cancer
Diagnosis
Pathological analysis
